Aragen Life Sciences is an API manufacturer based in India. It holds 3 active US drug master files across a filed portfolio of 4 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 May 2025 as NAI. Customs aggregates show $18.8M of exports covering 4,745 molecules to 49 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapali District, India | 3014738606 |
| Hyderabad, India | 3005851210 |
| Medchal Malkajgiri, India | 3011573185 |
| Molecule | Regulators | Docs |
|---|---|---|
| Dobutamine | US FDA | 1 |
| Moxifloxacin | SFDA (Saudi Arabia) | 1 |
| Pentosan Polysulfate Sodium | US FDA | 1 |
| Tramadol | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| US FDA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $9.9M | 35 |
| 2025 | Not reported | $18.8M | 49 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Aragen Life Sciences comes back tiered against every other supplier able to file there.
Start for free